[go: up one dir, main page]

NO974513L - Pyrrolidinyl-hydroksamsyre-forbindelser og deres fremgangsmåte for fremstilling - Google Patents

Pyrrolidinyl-hydroksamsyre-forbindelser og deres fremgangsmåte for fremstilling

Info

Publication number
NO974513L
NO974513L NO974513A NO974513A NO974513L NO 974513 L NO974513 L NO 974513L NO 974513 A NO974513 A NO 974513A NO 974513 A NO974513 A NO 974513A NO 974513 L NO974513 L NO 974513L
Authority
NO
Norway
Prior art keywords
hydroxy
alkoxy
formula
hydroxamic acid
acid compounds
Prior art date
Application number
NO974513A
Other languages
English (en)
Norwegian (no)
Other versions
NO974513D0 (no
Inventor
Fumitaka Ito
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO974513D0 publication Critical patent/NO974513D0/no
Publication of NO974513L publication Critical patent/NO974513L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
NO974513A 1995-03-31 1997-09-29 Pyrrolidinyl-hydroksamsyre-forbindelser og deres fremgangsmåte for fremstilling NO974513L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9500631 1995-03-31
PCT/JP1996/000820 WO1996030339A1 (en) 1995-03-31 1996-03-28 Pyrrolidinyl hydroxamic acid compounds and their production process

Publications (2)

Publication Number Publication Date
NO974513D0 NO974513D0 (no) 1997-09-29
NO974513L true NO974513L (no) 1997-09-29

Family

ID=14125824

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974513A NO974513L (no) 1995-03-31 1997-09-29 Pyrrolidinyl-hydroksamsyre-forbindelser og deres fremgangsmåte for fremstilling

Country Status (35)

Country Link
US (2) US5952369A (is)
EP (1) EP0817772B1 (is)
JP (1) JP3035356B2 (is)
KR (1) KR100258657B1 (is)
AP (1) AP625A (is)
AR (1) AR002729A1 (is)
AT (1) ATE231840T1 (is)
AU (1) AU693336B2 (is)
BG (1) BG62611B1 (is)
BR (1) BR9607750A (is)
CA (1) CA2213815C (is)
CZ (1) CZ306497A3 (is)
DE (1) DE69626009T2 (is)
DK (1) DK0817772T3 (is)
ES (1) ES2188743T3 (is)
HR (1) HRP960141A2 (is)
HU (1) HUP9900767A3 (is)
IL (2) IL117440A0 (is)
IS (1) IS4547A (is)
LV (1) LV11971B (is)
MA (1) MA23832A1 (is)
NO (1) NO974513L (is)
NZ (1) NZ304113A (is)
OA (1) OA10518A (is)
PE (1) PE43397A1 (is)
PL (1) PL322652A1 (is)
RU (1) RU2144917C1 (is)
SI (1) SI9620039A (is)
SK (1) SK129897A3 (is)
TN (1) TNSN96045A1 (is)
TR (1) TR199701082T1 (is)
TW (1) TW408111B (is)
WO (1) WO1996030339A1 (is)
YU (1) YU18696A (is)
ZA (1) ZA962476B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9701042A (es) * 1996-02-07 1998-05-31 Pfizer Compuestos del acido hidroxamico.
TNSN97092A1 (ar) 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
WO1998024431A1 (en) * 1996-12-02 1998-06-11 Kyorin Pharmaceutical Co., Ltd. Novel n-substituted pyrrolidine derivatives and process for preparing the same
CA2276074A1 (en) * 1997-01-10 1998-07-16 Merck & Co., Inc. Efficient synthesis of a chiral mediator
EP0982297A3 (en) * 1998-08-24 2001-08-01 Pfizer Products Inc. Process for the preparation of hydroxy-pyrrolidinyl hydroxamic acid derivatives being opioid kappa receptor agonists
KR100295740B1 (ko) * 1998-09-17 2001-11-05 박영구 N-치환된-하이드록시고리화알킬아민유도체의제조방법
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
JP2005508851A (ja) 2001-04-30 2005-04-07 ファイザー・プロダクツ・インク カッパーアゴニストとして有用なヒドロキシピロリジニルエチルアミン化合物の調製方法
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
EP1615883A1 (en) * 2003-04-14 2006-01-18 Warner-Lambert Company Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
UA89035C2 (ru) * 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
GB0821010D0 (en) * 2008-11-17 2008-12-24 Univ Warwick Plant development control composition
JP6254075B2 (ja) 2011-05-16 2017-12-27 バイオノミックス リミテッド カリウムチャネル遮断剤としてのアミン誘導体
KR101773331B1 (ko) * 2012-03-05 2017-08-31 닥터 레디스 레보러터리즈 리미티드 카파 오피오이드 수용체(κor) 작용제인 치환된 헤테로시클릭 아세트아미드
GB201210395D0 (en) * 2012-06-11 2012-07-25 Syngenta Participations Ag Crop enhancement compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3268539A (en) * 1963-05-20 1966-08-23 Universal Oil Prod Co Tertiary-aminoalkyl derivatives of diaryl substituted acetohydroxamic acid esters

Also Published As

Publication number Publication date
CA2213815A1 (en) 1996-10-03
US6110947A (en) 2000-08-29
KR100258657B1 (ko) 2000-07-01
AU693336B2 (en) 1998-06-25
ES2188743T3 (es) 2003-07-01
BR9607750A (pt) 1998-06-30
PE43397A1 (es) 1997-10-13
IL129479A0 (en) 2000-02-29
LV11971A (lv) 1998-02-20
KR19980703476A (ko) 1998-11-05
AR002729A1 (es) 1998-04-29
BG62611B1 (bg) 2000-03-31
ATE231840T1 (de) 2003-02-15
EP0817772A1 (en) 1998-01-14
PL322652A1 (en) 1998-02-16
HUP9900767A2 (hu) 1999-07-28
AP9600791A0 (en) 1996-04-30
EP0817772B1 (en) 2003-01-29
ZA962476B (en) 1997-09-29
TNSN96045A1 (fr) 2005-03-15
WO1996030339A1 (en) 1996-10-03
DK0817772T3 (da) 2003-05-19
CZ306497A3 (cs) 1998-07-15
YU18696A (sh) 1999-06-15
IS4547A (is) 1997-08-19
IL117440A0 (en) 1996-07-23
OA10518A (en) 2002-04-22
HUP9900767A3 (en) 2001-01-29
DE69626009T2 (de) 2003-08-14
BG101896A (en) 1999-01-29
SK129897A3 (en) 1998-11-04
JP3035356B2 (ja) 2000-04-24
MA23832A1 (fr) 1996-10-01
AP625A (en) 1997-12-24
NO974513D0 (no) 1997-09-29
SI9620039A (sl) 1998-08-31
HRP960141A2 (en) 1997-10-31
LV11971B (en) 1998-06-20
JPH11501048A (ja) 1999-01-26
DE69626009D1 (de) 2003-03-06
MX9707454A (es) 1998-07-31
TW408111B (en) 2000-10-11
CA2213815C (en) 2001-12-18
TR199701082T1 (xx) 1998-02-21
NZ304113A (en) 1999-01-28
US5952369A (en) 1999-09-14
RU2144917C1 (ru) 2000-01-27
AU5121196A (en) 1996-10-16

Similar Documents

Publication Publication Date Title
NO974513L (no) Pyrrolidinyl-hydroksamsyre-forbindelser og deres fremgangsmåte for fremstilling
CA2158108C (en) Compositions containing sertraline and a 5-ht1d receptor agonist or antagonist
NO20063382L (no) Nye kinolinderivater
TW200617001A (en) Novel glucitol derivative, its prodrug, their salt and diabetic therapeutic agent containing the same
JP3545416B2 (ja) フペルジンa誘導体、その製造およびその使用
MD3294738T2 (ro) Derivați de indol mono sau disubstituiți ca inhibitori ai replicării virusului Dengue
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
DE69501947D1 (de) SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
ATE189227T1 (de) Polyanionische benzyl-glykosiden als inhibitoren zur glatten-muskelzellen-proliferation
IS2503B (is) Ný efnasambönd
AU2002336311B8 (en) Bicyclic compound
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
PT746320E (pt) Intermediarios e inibidores da protease de hiv
NZ505220A (en) Arylpiperazines having activity at the serotonin 1A receptor, processes for their preparation and intermediates
IT1230859B (it) 2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
NO20060206L (no) Nye azetidinforbindelser
AU2016382372A1 (en) Sulfonamide derivative and preparation method and use thereof
DE602004020730D1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
DE60324685D1 (de) 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
WO2008042755A2 (en) Inhibitors of cognitive decline
RU2001911C1 (ru) Способ получени замещенных 1,2,3,4-тетрагидронафталинов или их фармацевтически приемлемых аддитивных солей кислоты
WO2006063113A3 (en) Ureas as factor xa inhibitors
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application